TJH is on the MCBS working group for the European Society for Medical Oncology. Q-DT reports grants from Pfizer and consulting fees from Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, and ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

according to data presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, and published concomitantly in the Journal of Clinical Oncology. Patients ...

For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Bowers added that to increase access to the latest drugs, the "cancer system" must be organized in such a way as to ...

Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b ...

Today we highlight research findings reported at ESMO 2024, the annual meeting of the European Society of Medical Oncology.